Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Discovery World

FEBRUARY 5, 2024

Opening keynote Following a change to the schedule, Juliet Williams of Kymera Therapeutics launched the event with a popular keynote talk ‘Solving Big Problems with Small Molecule Degraders’.

Small Molecule 163

Small Molecule Assay Development Production Science 163

DrugBank

JULY 24, 2024

Breaking New Ground with PROTACs One of the standout innovations in this space is the development of proteolysis-targeting chimeras, or PROTACs. These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

Drug Discovery World

OCTOBER 21, 2022

While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US 1 ), outcomes are still poor in certain cancers that do not respond to standard therapies. 3D bioprinted breast cancer tumours.

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

Drug Discovery World

DECEMBER 21, 2023

DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a hot topic. This well-read article featured in the DDW Winter 22/23 issue’s Cell & Gene Therapy Guide.

FDA Approval 148

FDA Approval Therapies Small Molecule Clinical Trials 148

Drug Target Review

JULY 4, 2023

Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Discovery World

FEBRUARY 13, 2024

Often this can be drug approvals, exciting research into hard-to-treat indications, or even regulatory updates that enable players within the sector to utilise the latest technologies and drive therapies to market faster, ultimately benefitting patients. Progress isn’t stagnant though.

Small Molecule 148

Small Molecule Drugs Therapies Pharmaceutical Companies 148

DrugBank

MAY 15, 2024

Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drug development for decades. The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding. One approach is to look beyond the traditional drug molecule.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

The Premier Consulting Blog

APRIL 18, 2024

Development of cell and gene therapies is growing rapidly, given the major advances in genomic technologies and increasing scientific understanding of genetic regulation and immunology. As in all nonclinical drug development programs, the goal is to identify potential safety issues in humans. Is fit-for-purpose?

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

Drug Discovery World

OCTOBER 4, 2022

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Discovery World

DECEMBER 26, 2023

Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis’ hereditary angioedema (HAE) drug candidate donidalorsen in Europe.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

Drug Discovery World

APRIL 5, 2023

CBC members are selected in five-year cycles and chosen for their knowledge and expertise in small molecule drug discovery and high-level capabilities to advance projects from target validation to clinical candidate selection.

Small Molecule 130

Small Molecule Cell Biology Laboratories Engineering 130

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

Vial

DECEMBER 11, 2023

In the decades since its identification in 1989, advances in clinical research for new Hepatitis C therapies and the introduction of direct-acting antiviral agents (DAAs) have led to viral eradication in more than 98% of patients, resulting in HCV crossing from manageable to being the first curable , chronic viral infection.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

PPD

OCTOBER 18, 2023

There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care. 1 With this growth comes increased demands for laboratory services at all steps across the development process.

Laboratories 52

Laboratories Assay Development Small Molecule Packaging 52

Drug Target Review

NOVEMBER 6, 2023

2 It is this complexity that necessitates powerful, targeted combination therapies. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required.

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

Drug Discovery World

FEBRUARY 27, 2023

For founders planning to launch their start-ups, specifically drug developers, there needs to be sound, foundational science with promising data that will enable you to push further down the drug discovery pipeline. Do you have any therapeutic targets in mind for your first small molecule drug candidate?

RNA 130

RNA Science Small Molecule Engineering 130

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Small molecule GLP1s?

Small Molecule 140

Small Molecule Trials Therapies Disease 140

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding. Northern Ireland “Northern Ireland is a medtech super-hub,” says Saleko.

Drugs 190

Drugs Science Therapies Targeted Protein Degradation 190

Drug Discovery World

MARCH 22, 2023

It will combine the use of novel Huntington’s disease drug targets from Aitia’s Gemini Digital Twins with UCB’s expertise in drug research and preclinical model systems in neurodegeneration, with the aim to accelerate the discovery of new therapies for people living with Huntington’s disease.

Targeted Protein Degradation 130

Targeted Protein Degradation Small Molecule Drugs Licensing 130

Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? We have already applied this approach to several important tumour targets where enhancements in TCR-T therapy may lead to important gains in clinical benefit, including mutated KRAS, NY-ESO, and HPV E7 antigens.

Immune Response 105

Immune Response Vaccine Therapies Small Molecule 105

Creative Biolabs

JUNE 29, 2023

At present, a large number of G protein-coupled receptor-targeted drugs have been marketed, and a large number of drugs are under development. GPCR is the most valuable target for drug development, and more drugs will be used to treat various diseases in the future.

Therapies 52

Therapies Small Molecule Research Drug Development 52

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

SEPTEMBER 26, 2022

Perhaps the biggest benefit drug repurposing brings is its potential to get treatments to patients faster than traditional means of drug discovery. A report by the medical charity LifeArc 1 puts the timeframe for a therapy brought to market through repurposing methods at anywhere from one to three years. References .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

PPD

JUNE 27, 2024

In recent years, AA has followed in the footsteps of other dermatology indications — including psoriasis and atopic dermatitis — with growing research and clinical studies focusing on small molecules with broad cellular effects (JAK and PDE4 inhibitors) and cytokine-specific molecules antagonists (IL-23, Th2 and IL17) to treat the condition.

Treatment 52

Treatment Clinical Trials Small Molecule Clinical Research 52

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. Noria) and PSMA Therapeutics Inc.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

The Pharma Data

JANUARY 25, 2021

–( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. 26, 2021 13:00 UTC. FREDERICK, Md.–( About VLX-1005.

FDA 52

FDA Small Molecule FDA Approval Drugs 52

PerkinElmer

JANUARY 21, 2021

Using drugs that are already on the market was the quickest path forward to evaluate these compounds and possibly help patients now because novel drug development typically takes years. Scientists needed to evaluate the field of potential drugs-and fast. COVID-19 is a difficult disease to understand and treat.

Treatment 52

Treatment Small Molecule Drugs Virus 52

DrugBaron

JULY 19, 2022

Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.

Small Molecule 100

Small Molecule Drugs DNA Pharma Companies 100

Drug Discovery World

APRIL 30, 2024

Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43

Therapies 130

Therapies RNA Vaccine Small Molecule 130

NIH Director's Blog: Drug Development

OCTOBER 11, 2022

For clinical researchers, click chemistry has emerged as a workhorse in drug discovery and the improved targeting of cancer chemotherapies and other small-molecule drugs. The approach also is being used to improve delivery of antibody-based therapies and to create new biomaterials. 2004 Jul;11(7):1009-1016.

Research 52

Research Small Molecule Science Clinical Research 52

Drug Discovery World

MAY 11, 2023

MitoRx Therapeutics is a pre-clinical stage rare disease biotech that wants to become the leading global developer of medicines arresting the progression of degenerative diseases drive by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease.

Targeted Protein Degradation 130

Targeted Protein Degradation Science Small Molecule Vaccine 130

Drug Target Review

MAY 1, 2024

T-DM1, for example, is approved in patients with HER2-positive breast cancer and residual invasive cancer following neoadjuvant therapy. What innovative strategies are being developed to improve drug stability? Jamie Rich, PhD is Senior Director of Technology, ADC Therapeutic Development at Zymeworks Inc.

FDA Approval 69

FDA Approval Drugs Organic Chemistry Small Molecule 69

Drug Discovery World

APRIL 25, 2023

Dawn Bio which is a drug discovery platform based on human embryo models for drug development for women’s reproductive health. Amplify Therapeutics boasts disease-modifying therapies for Gaucher disease and genetic subgroups of Parkinson’s disease.

Science 130

Science Small Molecule Disease Government 130

Sygnature Discovery

OCTOBER 10, 2023

“As part of building and extending Sygnature’s neuroscience drug discovery platform and future direction, we have an ethos to humanize the drug discovery process where feasible to elevate our level of understanding of how novel small molecule compounds work.

Small Molecule 52

Small Molecule Disease Drugs Clinical Trials 52

Drug Discovery World

AUGUST 5, 2022

Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. Why sponsors use external consultants.

Drug Development 130

Drug Development Drugs Pharma Companies International 130